Singapore Institute of Advanced Medicine (SGX:9G2) has extended its negotiations with EnGeneIC for a partnership after positive developments in EnGeneIC's dream vector technology, according to a Tuesday filing on the Singapore Exchange.
The parties agreed to extend the timeline for finalizing a definitive agreement by 60 days, now set for Feb. 1, 2025. The scope of the collaboration may expand to include EDV-based theranostics and boron capture therapy. All other terms remain unchanged.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。